The Evolving Understanding and Approach to Residual Cardiovascular Risk Management
View Full Paper
Ask AI
Bookmark
Share
Key result
Inflammatory, prothrombotic, and metabolic pathways drive residual CV risk and represent emerging therapeutic targets.
Why the study?
A significant residual risk of cardiovascular events remains despite optimal traditional risk factor management, driven by often unrecognized inflammatory, pro-thrombotic, and metabolic pathways.
Do therapies targeting inflammatory, pro-thrombotic, and metabolic pathways reduce residual cardiovascular risk in patients with ASCVD on optimal medical therapy?
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Should not yet change ASCVD practice; leaves open whether targeting these pathways reduces residual risk.
Structured PICO
Do therapies targeting inflammatory, pro-thrombotic, and metabolic pathways reduce residual cardiovascular risk in patients with ASCVD on optimal medical therapy?
P
Population
Patients with atherosclerotic cardiovascular disease or at high risk, with residual cardiovascular risk despite optimal traditional risk factor management.
I
Intervention
Therapies targeting inflammatory, pro-thrombotic, and metabolic pathways (including eicosapentaenoic acid, SGLT2 inhibitors, GLP-1 receptor agonists, anti-inflammatory agents, and low-dose anticoagulants).
C
Comparator
Standard of care including optimal traditional risk factor management (e.g., statins).
O
Outcome
Reduction in residual cardiovascular risk and recurrent atherosclerotic cardiovascular events.
This review highlights the importance of addressing residual cardiovascular risk through inflammatory, pro-thrombotic, and metabolic pathways beyond traditional LDL-C lowering.
Cite This Study
Dhindsa et al. (2020) conducted a review in Atherosclerotic cardiovascular disease (ASCVD). Anti-inflammatory, antithrombotic, and metabolic therapies was evaluated. Beyond traditional risk factors, inflammatory, pro-thrombotic, and metabolic pathways contribute significantly to residual cardiovascular risk and represent important targets for emerging therapies.
Topics
View Full Paper
Ask AI
Bookmark
Share